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Introduction
Remarkable progress has been made in the biological understanding of multiple myeloma and biology-based novel drug approaches, resulting in prolonged overall survival (OS) compared to the more dismal prognosis of 10-20 years ago. [1] [2] [3] [4] Current attempts in myeloma focus on further improving survival. Nevertheless, one challenge of this extended survival is that myeloma patients may acquire second malignancies, with an estimated incidence ranging between 2-10%. [1] [2] [3] [4] [5] Living longer with the disease, therefore, involves the risk of long-term sequelae, including both solid tumor and hematologic second malignancies.
Previous reports on second malignancies have focused on those developing subsequent to myeloma. Therapy-related risks have been suggested, such as prolonged melphalan exposure and immunomodulatory drugs (IMiDs). [4] [5] [6] [7] The risk of IMiDs has been put forward, since there are three randomized trials, [6] [7] [8] two in transplant eligible patients and one in transplant ineligible patients, which have not only reported on improved progression free survival (PFS) and improved OS, but have also shown a higher incidence of second primary malignancies (SPM) after prolonged lenalidomide treatment. SPM included hematologic and solid tumors, and in each trial their risk in the placebo group was 2-3% vs. 7-8% in the lenalidomide group, with the differences being both 3 statistically and clinically significant. [6] [7] [8] [9] There also appear to be hints that thalidomide may potentiate solid SPM, 5, 10 suggesting an IMiD class effect associated with melphalan exposure.
Our prior registry study covered almost 600 patients and ascertained malignancies before the multiple myeloma in 7% and SPM in 3%, 12 in agreement with others. [6] [7] [8] 10, 11 The frequency of solid tumors vs. hematologic malignancies, both before and after the diagnosis of myeloma, was 78%
and 22%, respectively, 12 cautioning oncologists that especially solid tumors are a more frequent phenomenon. Therein, we also demonstrated that the prognosis with SPM may be compromised and OS impaired (HR: 2.5, 95% CI 1.4-4.4). 12 Of note, while specific risk factors for SPM have not been unambiguously determined, some prior studies should be interpreted with caution due to small numbers of patients, inadequate or short-term follow-up, retrospective data collection, underreporting, no control group or other confounding factors, making specific risk factors difficult to identify in what is very likely a multifactorial process. 9, 11, 12 Moreover, most studies have neither explicitly deciphered the relevant question as to which factors favorably influence the occurrence of SPM, nor suggested mechanisms on how to avoid them.
Here, we performed a comprehensive registry analysis going beyond the traditional approach of looking at malignancies after the myeloma, rather than assessing both prior and subsequent malignancies in patients diagnosed with multiple myeloma with long-term follow up of 25 years. The focus of this analysis was to expand the data on SPM-and myeloma-specific risks in a wellcharacterized cohort, assessing patient-, myeloma, environmental-and treatment-related risks, cytogenetics and comparing our data with the European cancer registry GEKID. 13 To compare these risks, we estimated cumulative incidence rates for second malignancies and myeloma with Fine and Gray regression models. This provides subdistribution hazard ratios and analyses differences in the percentage of patients experiencing the respective event taking into account competing risks.
Methods
Patient description and data source. Consecutive patient data were retrieved from our institution's electronic medical records and an innovative research data warehouse called the University of
Freiburg Translational Research Integrated Database Environment (U-RIDE). The latter acquires
and stores all patient data contained in the electronic medical records at our hospital and provides immediate advanced text-searching capacity. Through U-RIDE, we could rapidly review data on patients with additional malignancies, both prior and synchronous, and after the diagnosis of myeloma (SPM). Patients' medical histories were reviewed based on their medical records and each case analyzed according to the onset of the first and subsequent malignancy. Depending on the stage and aggressiveness of their disease, patients received follow-up on a regular basis, both at our center and by their near-by practitioners. In all deceased patients, follow-up information was meticulously obtained as described. 9,12,14,15 4 All 744 patients included in this analysis were treated at our institution between 1/1997 and 12/2011, the median follow-up was 89 months, with long-term follow-up of second cancers and death from causes (myeloma) also being available for 25 years.
Bone marrow examinations were performed at diagnosis and during follow-up, along with metaphase karyotyping and interphase FISH for the detection of myeloma, myelodysplasia [MDS] or acute myeloid leukemia [AML]) as described. 10 as censored observations. Death without SPM (myeloma) and SPM were considered to be competing risks, and cumulative incidence rates were calculated using the Aalen-Johanson estimator. 16 This method is acknowledged to be more appropriate than the simple calculation of incidence rates as number of events divided by person-years, because the occurrence of censored observations and competing events has to be taken into account. 17, 18 We assessed the frequency of prior/synchronous additional malignancies and SPM in terms of host-, myeloma-and treatmentspecific characteristics. To compare these risks, we estimate cumulative incidence rates for SPM and death without SPM (myeloma) with Fine and Gray regression models. 19 This provides subdistribution hazard ratios and analyses differences in the percentages of patients experiencing the respective event within a certain period, taking into account the competing event. 20 In a first step, factors were assessed in univariate models. Finally, we set up a multivariate model with all factors considered to be relevant (i.e. age, gender, Ig-type, stage, anti-myeloma-therapy). As this was a registry based study, treatment decisions were not determined at random, and since the age and stage distribution changes in the course of time, 21 we considered it important to keep all these factors in the multivariate model. We further investigated 'MM diagnosis before 2004' (as a rough adjustment for changes in the course of time [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] ) and 'prior/synchronous AM' univariately as potential prognostic factors, 12 but did not keep them in the final multivariate model, as they showed no significant effect on SPM. Moreover, we compared our data with the European cancer registry GEKID to capture the age-and gender-matched German population, with the Surveillance, Epidemiology, and End Result Program of the National Cancer Institute (SEER) and prior analyses of other cancer registries. 3, 13 Our data were analyzed as of January 1st, 2014.
Results
Occurrence and distribution of different additional malignancies. Table 1 summarizes all 132 additional malignancies which were found in 744 consecutive patients: 31 (23%) were hematologic and 101 (77%) solid tumor malignancies. Of note, 105 patients with 1 additional malignancy, 12
patients with 2 and one patient had 3 additional malignancies, apart from myeloma (=118 patients with 132 AMs [105 + 2x12 + 3x1], Table 1 ). Assessing those malignancies that occurred prior/synchronously (n=83) vs. subsequently (SPM; n=49) to the myeloma, SPM were rarer. Both prior/synchronous and SPM groups showed less hematologic (17% vs. 35%) than solid tumor malignancies (83% vs. 65%, respectively). Frequent SPM were hematologic tumors, specifically MDS/AML. Most common solid tumor-SPM were colorectal-, gynecologic-/urothelial-, lung cancer and basal-cell carcinomas ( Figure 1 ).
Our cumulative incidence of all, hematologic and solid tumor SPM of 6.6%, 2.3% and 4.3%, respectively (Table 1) confirmed prior registry analyses and phase III trial results. [4] [5] [6] [7] [8] 22 These prospective, retrospective and metaanalysis data determined SPM frequencies at 4-6% (Table 2) . 6 Cumulative incidence for developing SPM for disease-, host-and therapy-specific factors. Table 3A and 3B summarize subdistribution hazard ratios (SHRs), 95% confidence intervals (CI) and pvalues both for SPM and death without SPM (myeloma) via uni-and multivariate analysis.
The cumulative incidence rates are also illustrated in Figure 2 for SMP, and in Figure Moreover, Figure 4 , b illustrates cumulative incidence rates of second cancer at 1, 5, 10 and 20 years which were 0.8%, 4.8%, 6.5% and 11.2%, respectively. Thus, the SMP risk increased primarily between 1 and 5 years and subsequently remaining at ~10%. The cumulative incidence rate after 1, 5, 10 and 20 years accounted for annual incidence rates of 0.77%, 0.99%, 0.67% and 0.59%, respectively, or ~0.8%/year. Standard annual incidence rates for cancer within the GEKID database were 452/100.000 for males and 341/100.000 for females, 13 accounting for annual cancer incidence rates of 0.4%/year. This annual incidence rate was therefore approximately 2-fold increased in myeloma patients compared to the GEKID data. 3, 12 Myeloma patients with 2 or more additional malignancies. As depicted in Suppl. Table 1, 13 patients had two or even three additional malignancies apart from the myeloma. In these 13 patients, myeloma occurred last, was flanked with both prior and subsequent malignancies or followed by 2 or even 3 additional malignancies in 5, 4 and 4 patients, respectively. The myeloma patient with three additional malignancies acquired prostate, colon cancer and B-CLL (patient #10). Therapyrelated MDS/AML (t-MDS/-AML) was observed in 4/13 patients, leading to AML-and MM-induced death in two and one patient, respectively. Of all multiple malignancy-bearing patients, 4/13 are currently alive. Conclusive cytogenetics were available in 7/13 patients, and in five it was possible to 7 examine both bone marrow plasma cells and additional tumor samples: of note, except in one with del13q14 aberration (patient #11), all others revealed favorable cytogenetics (Suppl. Table 1 ).
Cytogenetics. Karyotypes were available for 51% of our myeloma cohort. Although cytogenetics were not entirely complete as FISH was not routinely assessed in earlier years, we compared chromosomal aberrations in patients both with and without additional malignancies (Suppl. assessed at the time of the initial myeloma diagnosis, differences between both groups were less likely to be present than if the laboratory values had been compared at the time that the additional malignancy occurred. However, this is of lesser relevance since by that point of time the additional malignancy was already present, whereas our laboratory analysis was performed to decipher whether any easily measureable parameter may suggest the occurrence of an additional malignancy at a later time point.
The comparison of those 46 myeloma patients with SPM, comprising 7% of our cohort, vs. those without ( 93%, Suppl. Table 3A) showed a predominance of males (67% vs. 56%), higher smoking-(37% vs. 25%) and alcohol-(15% vs. 4%) exposure and a predominance of IgG myelomas in the SPM cohort (76% vs. 61%). With 61 years, the median age was identical. Other host-or myelomaspecific characteristics were not substantially different. Suppl. 
cycles, respectively. Corticosteroid-(median 11 vs. 6), alkylator-(8 vs. 6), lenalidomide-(9 vs. 4) and thalidomide-(10 vs. 5, respectively) exposure was increased, whereas anthracycline (both 2) and bortezomib (both 4) cycles were comparable. Single ASCT had been performed to a lesser extent in patients with vs. without SPM (25% vs. 38%, respectively). The same was true for tandemSCTs (9% vs. 14%), allo-SCTs (7% vs. 12%) and auto-allo-SCTs (7% vs. 11%, respectively).
Radiotherapy, albeit being performed less frequently in patients with vs. without SPM (29% vs.
40%) was increased in dose-(60 vs. 40 Gy) and field-intensity (2 vs. 1, respectively).
Discussion
In myeloma, second tumors have gained more attention in recent times as people with myeloma live longer. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] A limitation when studying second tumors is the fact that clinical trials are typically not designed to capture such data. Therefore, there can be substantial underreporting of second tumors (Table 2 ). An alternative approach is to use large central or well-kept population-based databases with long-term follow-up and compare risks to controls from the same database. Such strategies are powerful and provide large sample sizes, however, a limitation with central population-based databases is again underreporting, because most such resources have their main focus on primary cancers. Using our large population-based U-RIDE dataset matched with detailed clinical and treatment data for individual patients, we have expanded our current knowledge on this topic with long-term follow-up of myeloma and SPM for 25 years. 9, 12, 14, 25, 26 This U-RIDE dataset was not only suitable for truthful capture of additional malignancies in myeloma, but also more helpful and precise than physician recollection, pooled colleague opinion or clinical trials which were not originally designed to capture prior or subsequent malignancies. Such real-time availability of data to guide decision making and learn from well-kept databanks has already transformed other industries, and the growing prevalence of electronic medical records, along with the development of sophisticated tools for real-time analysis of identified data sets, is advancing the use of data-driven approaches in health care delivery.
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Prior analyses have suggested that longer lifespans with myeloma and specific risks may favor SPM. These may include risk factors such as age, gender, prolonged melphalan exposure, IMiDs, myeloablative therapy and radiation, [5] [6] [7] [8] 10 ,14 yet studies to elucidate the underlying mechanisms are ongoing. Moreover, conflicting results exist for both melphalan-and ASCT-risks: in an older study, long-term melphalan in 628 myeloma patients did not contribute to the pathogenesis of second solid tumors, 28 whereas another analysis by the Medical Research Council in 648 patients reported of a significant relationship with both the length and amount of melphalan, but no relationship for cyclophosphamide, 29 supporting a recent metaanalysis. 30 In line, disparate results on MDS and other SPM after ASCT have been reported, such as a high 5-year cumulative incidence for MDS of 18% in one study, 25 whereas in a larger analysis of ASCT vs. prolonged conventional chemotherapy that prolonged standard-dose alkylators prior to ASCT, rather than myeloablative treatment, are associated with MDS/AML. 26 In addition, MDS-associated cytogenetic abnormalities have been linked to the development of overt clinical MDS and AML.
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Of note, two recent first-line IMiD studies, one with lenalidomide and dexamethasone (Rd/MPR) vs.
ASCT, 4 and the second using Rd in transplant-ineligible patients 5 did not observe excessive SPM risks. The SPM rate in the Rd/MPR vs. ASCT study was 4.3%, and showed no difference with vs.
without lenalidomide maintenance, 4 while the rate in the non-transplant eligible elderly study was 3% with continuous Rd, 6% with 18 months Rd and 5% with MPT. 5 This confirms prior studies 6, 7 suggesting that the increased risk of SPM among patients treated with IMiDs is related to prior or concurrent melphalan use. 4, 5 In line, a recent metaanalysis revealed an increased risk of developing hematological SPM in patients with lenalidomide and melphalan, suggesting alternative lenalidomide schedules, such as with cyclophosphamide or alkylator-free combinations. 30 Moreover, myeloma-related factors, such as Ig-type and gene polymorphisms, as well as host genetics that define susceptibility to SPM, seem to be important. Therefore, genome-wide association studies and gene expression microarray analysis of patients with and without SPM are being performed. 9, 11, 12, 14, 32 In our prior registry analysis we found that the majority of myeloma patients had additional solid tumors rather than hematological malignancies. 12 These results were confirmed in this even larger U-RIDE-dataset. In solid tumor patients, we confirmed main tumor clusters. IgG-myeloma and decreased in bortezomib-treated patients. Even though competing risks have to be interpreted with caution due to confounding factors, these results underline the value of population-based studies, complementing clinical trials and supporting registry data. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Of interest, our cytogenetic analyses revealed that indolent myeloma with favorable cytogenetics, combined with its improved prognosis and long latency, allow the occurrence of additional malignancies to become an important challenge.
Our comparison of incidence rates of SPM among myeloma patients to annual cancer incidence rates obtained from the European cancer registry GEKID 13 showed a 2-fold elevation in SPM rates in myeloma patients. While SEER-data confirmed our cumulative incidence rate of developing SPM 10 after 25 years of 10%, that of death from all other causes (myeloma) was 90%, 3 but 83% in our U-RIDE data set. Both SEER and U-RIDE registries involved both overlapping and different treatment periods (U-RIDE: 1997-2011; SEER: 1973-2008), but verified that the development of SPM remains substantially lower than the risk of death from myeloma. [1] [2] [3] [4] [5] [6] [7] [8] [9] Nevertheless, both curves slightly converge, urging us to persistently reassess SPM in the course of the disease.
In line with prior registry analyses, our data can be criticized for the heterogeneous treatment of patients, that confounding and competing risks exist and that U-RIDE and SEER analyses involved both overlapping and different treatment periods. Nevertheless, strengths of our U-RIDE data were that we undertook a very comprehensive look at second malignancies and risks in a wellcharacterized consecutive myeloma cohort, that long-term follow-up of second cancers and death from myeloma was available for 25 years and that we compared our data with the European cancer registry GEKID 13 and prior reports ( Table 2) . For cumulative incidence rates of SPM and myeloma death, we used the Fine and Gray model, which provides subdistribution hazard ratios and analyses differences in the percentages of patients experiencing the respective event within a certain period, taking into account competing events. 19, 20 Cumulative incidence rates were both assessed in univariate and multivariate models, within the latter including all relevant factors, such as patient-, myeloma-and treatment-related risks. Since we and others have demonstrated previously that patient characteristics and treatment modalities change over long time periods, 1, 9, 12, 14, 15, 21 adjustments by means of regression models are necessary, as meticulously performed here. In support of our data, prior analyses have suggested similar cumulative incidence rates for myeloma and SPM as summarized in Table 2 .
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In conclusion, this large updated registry analysis reminds us that given the remarkable progress in myeloma, second cancers represent long-term complications, which may evolve as a necessary consequence of life-saving treatment, patients aging with cancer, multiagent drugs being used, prolonged treatment exposure, better surveillance programs, our greater awareness of SPM and improved diagnostic measures to detect them. 1, 9, 12, 14 The risks for SPM identified by this analysis with long-term follow-up of 25 years were disease-and patient-(IgG, males, advanced stage) as well as therapy-related (therapy extent, IMiDs; Figure 2 ). SPM may therefore emerge as an important after effect in myeloma, and living longer with the disease. Our large U-RIDE analysis provides clearer answers for cumulative incidence risks for SPM and myeloma, prompting us to discuss treatment risks and benefits with our patients and to stay well informed as further knowledge on prior cancers before and SPM after the myeloma become available. Hematologic malignancies occurred more frequently as SPM than p/s malignancies (albeit lymphomas were also frequent as p/s malignancies. Frequent solid tumors were colorectal, gynecologic/urothelial and prostate cancer. Except for colorectal cancer, these all occurred more frequently p/s to the myeloma. Skin tumors, as melanoma and basal-cell carcinomas, occurred also more often p/s to the myeloma, with basal-cell carcinomas appearing as SPM as well. 
